Great to see University of Pennsylvania and their CAR-T work in the news. Amazing to think that the UPenn SpyCatcher inventors are on PTX's SAB (Scientific Advisory Board).
"PTX has acquired the exclusive global licence to a universal immune receptor (UIR) platform from the University of Pennsylvania (Upenn) and a non-exclusive licence to use the Spytag/SpyCatcher molecular binding system used by the UIR platform.
The company intends to use these licences and technology to build OmniCAR, a next generation cell therapy platform. OmniCAR has the potential to be a game changer for the company with UIRs having the potential to address a number of issues with the current (first generation) CAR-T cell therapies, allowing for more safe and effective treatment of blood cancers and boosting the potential use of CAR-T cell therapy in solid tumours, something that has proved elusive to date. The platform is currently in the preclinical stage of development with PTX seeking to undertake a combination of internal and external development."
